It has been quite a while since the community had fundraised for the MMTP senolytics project; unfortunately, the start of the experiment was delayed due to a number of issues encountered along the way. However, today, we are delighted to announce that the experiment has been approved and has finally launched!
The COVID-19 situation
To really top this off and add some extra problems, the study was just about ready to launch when COVID-19 made an appearance. Labs were closing down and supplies and deliveries were erratic, but I managed to get everything together and got ready to begin, thanks to all the people and scientists that are still working to make science happen.
A total of 40 C57BL mice will be treated with a combination of senolytics (ABT-263, ABT-199, dasatinib, isoquercetin) and compared to 40 control mice. The mice were all 18 months old when the experiment started. Blood samples have been taken to determine aging marker analyses before the start of the senolytic treatment, and subsequent blood draws will happen during the study to track changes and determine the health of the animals in addition to a range of other murine health parameters.
Stay tuned for more news!
Write a comment: